Leap Therapeutics, Inc.

Tensha Therapeutics, Inc.

Michael H Kagey

Steven B Landau

Cynthia A Sirard

A method of treating a cancer in a subject in need thereof is disclosed. The cancer can be an esophageal cancer, a uterine cancer, a liver cancer, or a cholangiocarcinoma. The method comprises administering to the subject an effective amount of an anti-Dkk-1 antibody or antigen binding-fragment thereof, wherein the subject is determined to have a constitutively activating mutation of the beta-catenin protein.

Use of beta-catenin as a biomarker for treating cancers using anti-Dkk-1 antibody

Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody

The present invention relates to treatment of a condition associated with hyperinsulinaemia using the compounds described herein.

Treatment of conditions associated with hyperinsulinaemia

The present invention relate to bromodomain inhibitor compounds, pharmaceutical compositions comprising the bromodomain inhibitor compounds and methods of treating a disorder responsive to fee modulation of a BET family polypeptide using the compounds and pharmaceutical compositions described. (Formula (I)) 

Growing community of inventors

Arlington, MA, United States of America

Michael H Kagey